PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Amniotics’ PulmoStem receives positive safety data

Treatment is a lung-specific stem cell therapy designed for hospitalised patients with respiratory infections.

Amniotics AB has announced that safety criteria have been met in the second cohort of its concluded phase 1b clinical trial investigating PulmoStem.

The treatment is a lung-specific stem cell therapy designed for hospitalised patients with severe respiratory infections triggered by COVID-19, influenza A, Metapneumovirus and respiratory syncytial virus (RSV). These diseases, if left untreated, can lead to acute respiratory distress syndrome.

The central aim of the study – which was conducted in Sweden – was to evaluate the tolerability and safety of intravenous dosing when incorporating PulmoStem. The trial also included secondary and exploratory endpoints related to biomarkers of the inflammatory response, lung regeneration and other clinical endpoints.

PulmoStem is derived from full-term amniotic fluid and is expected to be effective in various chronic and acute lung conditions through modulation of the immune response and anti-fibrotic capabilities.

The dose escalation committee has subsequently announced that no dose-limiting safety findings emerged during the second dose level of two million cells per kilogram of body mass. Amniotics has also previously revealed that the research ended after the second dose level and that the study report is expected to be released later in 2023.

Marcus Larsson, chief executive officer at Amniotics, is confident that the product can make a difference: “An exciting and at the same time expected result. That the dose escalation committee’s review shows safety at the dose of two million cells per kilogram is positive for the continued development of PulmoStem and we are now looking forward to the data from the final report.”

Meanwhile, PulmoStem is being investigated for lung transplantation treatment and chronic lung disease, including idiopathic pulmonary fibrosis.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026